Eli Lilly: As donanemab filing approaches, execs 'even more confident' in data package
Eli Lilly had a strong Q2, but unsurprisingly analysts don’t want to talk much about drugs already approved — their eyes are set firmly on Alzheimer’s hopeful donanemab, a potential blockbuster in the making.
Lilly CEO David Ricks faced a wall of questions Tuesday from analysts on the drugmaker’s Q2 earnings call looking to paint a picture of Lilly’s hand as it prepares to file a BLA for donanemab later this year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.